RecruitingMajor Depressive Disorder

Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine

Eligible age

18–65 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The main purpose of this study is to investigate the effects of ketamine on decision-making and emotion processing in a sample of individuals diagnosed with Major Depressive Disorder (MDD).

Sponsor: Emory University

You may qualify if…

✓ MDD Patients:
✓ willing and able to give written informed consent
✓ men or women, 18-65 years of age
✓ primary diagnosis of DSM-V MDD, current, as diagnosed by the SCID-I
✓ score of ≥20 on the Beck Depression Inventory, which will include patients characterized as having "moderate/severe" (20-28) or "very-severe" (29-63) depressive symptoms
✓ off all antidepressant therapy for at least 8 weeks prior to the baseline visit
✓ Healthy Controls:
✓ willing and able to give written informed consent

You may not qualify if…

✕ MDD Patients:
✕ history of any bipolar disorder or psychotic disorder
✕ active psychotic symptoms of any type
✕ substance abuse/dependence within 6 months of study entry (as determined by SCID)
✕ unstable cardiovascular, endocrinologic, hematologic, hepatic, renal, or neurologic disease (as determined by physical examination and laboratory testing), including upper respiratory disease or asthma, glaucoma or porphyria.
✕ active suicidal ideation as determined by a score ≥3 on the Columbia Suicide Severity Rating Scale (C-SSR)
✕ use of any recreational drugs as confirmed by urine drug screen at the time of scanning
✕ pregnancy or lactation

Where it's recruiting

Georgia

Atlanta

Source: ClinicalTrials.gov · NCT05327699 · last updated 2026-05-26